Valeant Pharma (VRX), Progenics (PGNX) Announce Commercial Launch of RELISTOR as OIC Treatment
Tweet Send to a Friend
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
